Pruritus
Study register · detail Fallserie · Pruritus · 2022

Cannabinoids for the treatment of refractory neuropathic pruritus in amyotrophic lateral sclerosis: A case report.

Clear benefit GRADE Very low 12 citations
Samplen = 1 Pat.
Durationunclear
EndpointPruritus score
Blindingn.a.
DesignFallserie
Cannabinoidkombination
THC:CBD1:1
Routeoral
Key finding

The patient showed an improvement in pruritus score from 7/10 to 3/10 under oral cannabinoids with initially increased sedation, which however developed quickly.

Summary

Single case report (n=1) on refractory neuropathic pruritus in an ALS patient; oral cannabinoid (balanced THC/CBD) reduced pruritus score from 7/10 to 3/10. Initial sedation, rapid development of tolerance. No systematic evidence, pure case series.

P
Population60-year-old patient with ALS and refractory neuropathic pruritus (n=1)
I
InterventionOral balanced cannabinoid (THC/CBD) from a licensed manufacturer
O
OutcomeImprovement of pruritus score from 7/10 to 3/10; initial sedation which resolved quickly
Confidence in the evidence
Very low

The lowest GRADE level, the effect estimate remains uncertain.

Downgraded for
Imprecision
Quality profile
Sample size
Blinding
Effect size Clear benefit
Citations / year
Authors
Lou K, Murphy S, Talbot C
DOI 10.1177/02692163211045314
Design: Fallserie
Share
Abstract
Background: Neuropathic symptoms have a wide variety of manifestations, ranging from pain to pruritus. Neuropathic pruritus is a type of chronic pruritus related to damaged small fibers. Cannabinoids have evidence to manage neuropathic symptoms. We present a case of refractory neuropathic pruritus that was successfully managed with the use of oral cannabinoids. Case Presentation: A 60-year-old male with amyotrophic lateral sclerosis with ongoing pruritus despite the use of standard neuropathic therapies. Possible Course Of Action: Sodium channel and N-methyl-D-aspartate receptor antagonists have evidence for neuropathic symptoms but can cause significant gastrointestinal side effects. Prescription cannabinoids such as nabiximol can be cost prohibitive to use in practice. Synthetic tetrahydrocannabinol products are dose limited by psychoactive side effects. Formulation Of A Plan: A balanced oral cannabinoid from a licensed producer was preferred as it has evidence for neuropathic symptoms and is generally well tolerated. Outcome: The patient showed improvement to his pruritus score from 7/10 to 3/10. There was initial increased sedation but tolerance developed quickly. Lessons Learned From Case: Cannabinoids are possibly safe and effective in management of neuropathic pruritus. View On Research Problems: Additional research is needed to establish efficacy and safety.

The impediment to action advances action. — Marcus Aurelius